Member Info for Bermudashorts

WTP

Below is a copy of a post I made a couple of weeks ago:-

Bermudashorts

Posted in: SCLP

Posts: 11,996

Price: 12.75

No Opinion

RE: SCIB1 trial15 Jul 2022 19:56
Johnny,

Yes an extra study centre will help.

The most significant protocol change for the SCIB1 trial is opening the it up to patients being treated with Opdivo and Yervoy. Apologies if I'm teaching anyone to suck eggs here, but for the sake of any newcomers, originally the study was designed to test SCIB1 in combination with Keytruda where Keytruda was being prescribed as the standard of care treatment. However, for reasons that are irrelevant to this post, the trial has taken so long to get going that things have moved on and the doublet therapy of Opdivo plus Yervoy is now the standard of care for many patients. With the best will in the world, if a doctor believes that Yervoy+Opdivo is a better treatment option than Keytruda for a patient, they're not going to recruit that patient to a trial testing SCIB1 with Keytruda.

Recruitment was never going to be quick to this trial, but the changing treatment landscape had shrunk the suitable patient pool and meant that it would have been incredibly slow and difficult to fully recruit. Opening the trial up to patients being treated with Yervoy+Opdivo should help.

corr event

It was also tweeted by the German Embassy in London so I think we have to accept that the even took place as reported. I have no idea whether it's Rick Holland or not, but the gentleman standing next to Boris is Sir Paul Nurse, Chief Exectutive of the Francis Crick Institute, Nobel prize winner, ex president of the Royal Society and general legend in his own time.

Good to see Parsortix being noticed in Chicago - 'Find out what's trending, what's new, and what's notable at the 2022 American Association for Clinical Chemistry (AACC) expo in Chicago.'

https://www.prweb.com/releases/10_developments_at_aacc_2022_in_chicago_per_kalorama_information/prweb18815847.htm

https://www.bizjournals.com/philadelphia/news/2022/07/27/angle-liquid-biopsy-plymouth-meeting-parsortix.html

BOJO - yes definitely a question for AH although I'd assume the question is more relevant to ctDNA rather than CTC liquid biopsies.

The beauty of Parsortix is that CTC and ctDNA liquid biopsies can be complementary to one another and it's possible to obtain both from the same blood draw. Large medtech companies, full service CROs etc. will want to be able to offer both to its customers.

The strength of ctDNA is when it's used as a tool for fast, high throughput mass screening to detect cancer early. Any cases flagged could potentially then be verified with a CTC liquid biopsy which would provide the necessary data on protein and RNA expression to inform on the best treatment option for that patient.

Imagine a world where high risk patients are routinely screened with a simple blood test. are diagnosed and have a treatment plan within a few days. No more waiting until your tumour is large enough to cause symptoms and show up on imaging before you're even aware of it and no more angst filled weeks waiting for tissue biopsies before you receive your targeted treatment. No more taking that treatment and only finding out that your tumour has stopped expressing the protein being targeted when your cancer progresses. We have quite a way to go to reach that stage, but the field is emerging in front of our eyes and that's where we're heading.

I should stress that this isn't a ramp, we each need to decide for ourselves whether Angle will be successful in capturing this emerging market - clearly having the first ever FDA approved system is a good start.

IMO

Some nice coverage here for AGL.

Note the Illumina/Grail comments bearing in mind their largest shareholder is Baillie GIfford.

https://www.labiotech.eu/in-depth/liquid-biopsies-cancer-detection/

Ray,

Thanks - have just spotted your 17.05 and 17.06 which I assume are the posts DeAar is referring to. All makes sense now.

Ray, would be good if you can comment - a little concerning if lse system is so poor that a glitch can cause someone's post to appear under someone else's name.

Excellent update today from Ergomed. strong revenue and order book growth with £12 cash after the purchase of Adamas and debt free. Note the increase in the RCF to £80m - seems they are still very much in acquisitive mode.

I'm not invested so this may already have been posted, but Synairgen's CSO Dr Phillip Monk is presenting at the World Vaccine and Immunotherapy Congress in San Diego later in the year.

https://www.terrapinn.com/conference/world-vaccine-immunotherapy-congress-west-coast/speakers.stm

Very sorry to read your earlier post and that you've needed another spell in UCLH. Hope the heat didn't add to any discomfort and that you'll be well enough to get home today. Take care and look after yourself.

JohnnyB - thanks for that

Matt - Whilst it's true that any overspend will be funded by Scancell shareholders, they are the ones who stand to benefit from the UKRI grant if the trial is successful. Not only should it increase the valuation for the ImmunoBody platform, but they're also getting the first clinical trial for Avidimab thrown in - again success should be reflected in any valuation. So doesn't seem unreasonable.

There has some discussion around the CLNs over the past day or so and a couple of thoughts struck me.

Firstly, thank goodness the redemption dateswere put back to 2025. I know one or two of the larger investors here had real concerns over the short term of the original agreements and it's clear with the passage of time that they were absolutely right. The original redemption dates would have been just a few weeks away from today - on 12th August and 10th November 2022. Can you imagine the discussions we'd be having if those dates were looming?

Secondly, no matter what your opinion of Cliff Holloway, he did at least bring Redmile on board and leave the Company well funded to weather the covid storm and do justice to its pipeline. The biotech. sector has really suffered over the last year and it would have been a really tough environment in which to raise had Cliff been unsuccessful in getting the second round of Redmile funding away.

Matt - I'm not sure I agree. The grant given to Scancell was very similar to that given to the Oxford team at the same stage of development. In applying for thesse grants, Companies have to supply fully costed budgets. Scancell applied for funding cover preclinical development and initiate clinical trials - that's what they asked for and that's what they got. It's all taxpayers money and I'm struggling to see why they would/should have received more.

violindog - Covidity was already in development when Redmile invested and may well have played a part in attracting their attention in the first place.

BOJO - re. your 21.03 yesterday.

As you know Angle intend to offer a LDT using Parsortix and their HyCEAD-Ziplex for analysis of RNA expression to predict whether women with a pelvic mass have a malignant of benign growth.

They have already run 2 successful clinical trials in ovarian cancer, one in Europe and one in the US. The results showed that they were able to predict the presence of ovarian cancer with a high degree of accuracy, achieving a ROC-AUC of 95.1%. I'm not sure whether you're familiar with ROC-AUC, but basically between 80% and 90% is classified as good and over 90% is excellent. So you can see that a result of 95.1% is pretty impressive. According to Angle the test achieved higher sensitivity and specificity than any other test available for the same clinical application.

Following optimisation of the assay a pre- verification study in 54 patients was carried out and we've been told this was successful, allowing the full verification study in 200 patients to commence - it's the results from this study that we are waiting for.

We will be given just headline results, but I'm not sure exactly what details to expect. The purpose of the study is to support accreditation of both the US and UK labs thereby enabling Angle to sell the ovarian cancer LDT, so that is the measure of success I'll be looking for - ie. are they good enough for accreditation and to market the LDT?

Just noticed that the status for the ovarian study on clinicaltrials.gov was updated on 28th June to completed, headline results not long now hopefully.

Surrey,

No wonder you're concerned about costs if you think they're marketing directly to clinicians - they're not.

Really good to see the quality of institutions investing in Angle with Baillie Gifford increasing their ownership to 5.73% of the Company. A reminder of the comment from Trinity Delta following the recent raise:-

'The quality of new and existing institutions supporting the raise, achieved during notably challenging market conditions, is a testament to the strength of the investment case.'

As pointed out by SK on Advfn, Ballie Gifford is the largest shareholder of Illumina and they will have a deep understanding of the sector. If any here aren't familiar with Illumina then it's worth a bit of research to understand the significance of this RNS.

https://www.londonstockexchange.com/news-article/AGL/holding-s-in-company/15549325

Feverman,

Re. your 12.21 - seriously?

You think what's needed is for AN to show some humility and admit the company doesn't have all the answers? Sounds very much like an emotional response to a personal issue with AN rather than an objective evaluation of Angle and a surprising view given your background as outlined in previous posts.